Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations

Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic calicheamicin payload via an acid labile linker. InO has shown significant activity in relapsed and refractory B-cell precursor acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Jeremy D., O’Brien, Maureen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435844/
https://www.ncbi.nlm.nih.gov/pubmed/37600823
http://dx.doi.org/10.3389/fimmu.2023.1237738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435844/
https://www.ncbi.nlm.nih.gov/pubmed/37600823
http://dx.doi.org/10.3389/fimmu.2023.1237738

Ejemplares similares